Subscribe

Genitourinary Cancers

Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive
By Nadia Jaber
Personalized Medicine, Bladder Cancer, Genitourinary Cancers
October 2023, Vol 14, No 5
It was once thought that after guiding the development of male sex organs in a fetus, the Y chromosome did not do much else. But over the past few years, results from multiple studies have challenged that belief.
Read Article
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By Wayne Kuznar
NCCN, NCCN 2023 Conference Highlights, Renal-Cell Carcinoma, Genitourinary Cancers
June 2023, Vol 14, No 3 - Online Only
Surgery is typically the gold standard for patients with biopsy-proven, clear cell, renal cell carcinoma with no evidence of metastatic disease, said Eric Jonasch, MD, in a session during the 2023 National Comprehensive Cancer Network Conference. In this setting, there is probably not a role for systemic neoadjuvant treatment, as response rates of 15% to 45% have been recorded with axitinib (Inlyta), sunitinib (Sutent), and other tyrosine kinase inhibitors.
Read Article
New Subgroup Analysis Confirms Efficacy and Safety of Darolutamide Across Different Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
By Anne Rowe
ASCO GU 2023 HIGHLIGHTS, Prostate Cancer, Genitourinary Cancers
April 2023, Vol 14, No 2
An analysis from the ARASENS trial showed that the addition of darolutamide to androgen-deprivation therapy and docetaxel significantly improved overall survival in subgroups of patients with metastatic hormone-sensitive prostate cancer with high-volume and high-risk disease and should be considered the new standard of care for this patient population.
Read Article
Addressing Health Equity in Bladder Cancer Care
By Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS, Bladder Cancer, Genitourinary Cancers
April 2023, Vol 14, No 2
During the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts identified some of the key challenges to achieving health equity in bladder cancer care and discussed what can be done to improve access to clinical trials, mitigate financial toxicity, and promote value-based care.
Read Article
Choosing Adjuvant Treatment for Patients with RCC Requires Careful Consideration of Risks and Benefits
By Wayne Kuznar
ASCO GU 2023 HIGHLIGHTS, Renal-Cell Carcinoma, Genitourinary Cancers
April 2023, Vol 14, No 2
The decision to use adjuvant therapies in patients with renal-cell carcinoma (RCC) should be based on risk, patient goals, and shared decision-making. This topic was explored in a presentation by Matthew Zibelman, MD, Associate Professor, Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Read Article
Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer
FDA Approvals, News & Updates, Bladder Cancer, Genitourinary Cancers
February 2023, Vol 14, No 1
On December 22, 2022, the FDA accelerated the approval of mosunetuzumab-axgb (Lunsumio; Genentech), a bispecific CD20-directed CD3 T-cell engager, for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. The FDA granted this indication breakthrough therapy and orphan drug designations.
Read Article
Second-Line Treatment with Sacituzumab plus Pembrolizumab Shows Promising Activity in Metastatic Urothelial Cancer
By Phoebe Starr
Genitourinary Cancers
August 2022, Vol 13, No 4 Online Only
The addition of sacituzumab govitecan (Trodelvy), an antibody–drug conjugate, to the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging antitumor activity in checkpoint inhibitor–naïve patients with metastatic urothelial cancer, according to an analysis of the results of cohort 3 from the phase 2 TROPHY-U-01 clinical trial.
Read Article
Olaparib plus Abiraterone Combination Significantly Improves Radiographic PFS in Men with Metastatic Castration-Resistant Prostate Cancer
By Phoebe Starr
Genitourinary Cancers
August 2022, Vol 13, No 4 Online Only
Combining the PARP inhibitor olaparib (Lynparza) with abir­aterone acetate (Zytiga) led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) versus abiraterone alone in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) status, according to results of the phase 3 PROpel trial.
Read Article
De-escalating Chemotherapy Possible in Low-Risk Patients with Advanced Testicular Cancer
By Wayne Kuznar
ASCO, Genitourinary Cancers
April 2020, Vol 11, No 2
San Francisco, CA—De-escalating chemotherapy based on a negative positron- emission tomography (PET) scan after 2 cycles of treatment is safe and feasible in most patients with low-volume metastatic seminoma, the most common type of testicular cancer, according to results presented at the 2020 Genitourinary Cancers Symposium.
Read Article
A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies
By Wayne Kuznar
ASCO, Genitourinary Cancers
April 2020, Vol 11, No 2

San Francisco, CA—Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision- making process.

Read Article

Page 1 of 2

  • 1
  • 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.